Device sets $5000 a year cost challenge for RA anti-TNF drugs
This article was originally published in Scrip
Executive Summary
Rheumatoid arthritis patients who are not responding to conventional first-line drug treatment could, in three years, instead receive neuromodulation therapy from a device that is being developed by an emerging Californian medtech firm and that could cost around $5000 a year to provide. That represents a significant potential cost advantage and, therefore, market threat to anti-TNF drugs ad biologics that can cost $20,000-$30,000 a year or more.